Sareum Holdings plc

Equities

SAR

GB00BMC3RJ87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:05 2024-04-26 am EDT			5-day change	1st Jan Change
26.25 ^GBX	0.00%		+10.53%	-55.88%

Apr. 23	Sareum Issues Shares to Settle Facility with RiverFort	MT
Apr. 19	Sareum falls as issues shares to RiverFort Global	AN

Sareum Holdings plc Reports Earnings Results for the Half Year Ended December 31, 2023

March 28, 2024 at 03:00 am EDT

Sareum Holdings plc reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net loss was GBP 2.51 million compared to GBP 1.45 million a year ago. Basic loss per share from continuing operations was GBP 0.036 compared to GBP 0.021 a year ago.

Latest news about Sareum Holdings plc

Sareum Issues Shares to Settle Facility with RiverFort	Apr. 23	MT
Sareum falls as issues shares to RiverFort Global	Apr. 19	AN
Northcoders launches bootcamp; Schroder invests	Apr. 04	AN
Sareum ups retail offer; SThree nabs former ITV exec	Apr. 02	AN
Sareum to Increase Retail Offer After Oversubscription	Apr. 02	MT
EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost	Mar. 28	AN
Sareum Holdings plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 28	CI
Sareum Holdings touts new patent allowance for autoimmune therapy	Mar. 15	AN
Sareum Bags European Patent for Kinase Inhibitor for Autoimmune Disease	Mar. 15	MT
Sareum shares slump on widened loss and funding talks	Mar. 12	AN
Sareum Wraps Up Single Ascending Dose, Food Effect Study in Early-stage Trial of Autoimmune Disease Drug	Feb. 15	MT
Sareum hails safety profile for SDC-1801 after phase 1 trial	Feb. 15	AN
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets	Feb. 15	AN
Sareum Holdings plc Announces Completion of the Single Ascending Dose Part and the Food Effect Study of its Phase 1a Clinical Trial for the Lead Programme SDC-1801	Feb. 15	CI
Sareum's Partner Signs Deal with US Biopharma Company for Cancer Growth Blockers	Jan. 02	MT
London stocks make largely soft start to 2024	Jan. 02	AN
AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal	Jan. 02	AN
Sareum soars as partner agrees SRA737 licence with US biopharma firm	Jan. 02	AN
EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer	Dec. 14	AN
Sareum Holdings plc Provides Update on Operational Activities and Pipeline Progress	Dec. 14	CI
Transcript : Sareum Holdings plc - Shareholder/Analyst Call	Dec. 14
Sareum Holdings draws down on equity prepayment facility	Nov. 23	AN
Sareum Draws Down GBP300,000 from Equity Prepayment Facility	Nov. 23	MT
Sareum Doses First Subjects in Food Effects Part of Lead Asset Trial	Nov. 09	MT
EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings	Nov. 09	AN

Chart Sareum Holdings plc

Duration

Period

More charts

Company Profile

Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.

Sector

Biotechnology & Medical Research

Calendar

2024-10-14 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.2625 GBP

Average target price

1.76 GBP

Spread / Average Target

+570.48%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAREUM HOLDINGS PLC	-55.88%	34.93M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs